Skip to main content
Signal8

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

$VNRXPress releaseApr 23, 2026, 8:12 AM ET

VolitionRx received acceptance from the NYSE American for its plan to regain compliance with continued listing standards, granting the company until August 6, 2027 to cure the deficiency. The exchange had notified the company in February that it failed to meet equity requirements due to reported losses in recent fiscal years and was ineligible for market cap exemptions.

Key figures

Compliance deadline
August 6, 2027
Min equity 2yr losses
$2.0 million
Min equity 3yr losses
$4.0 million
Min equity 5yr losses
$6.0 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    VNRX: VolitionRx Announces Acceptance of Compliance Plan by NYSE American — AI Analysis | Signal8